{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:30:38Z","timestamp":1773379838116,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"KAKENHI","award":["JP17K11306"],"award-info":[{"award-number":["JP17K11306"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4520-5","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T10:49:40Z","timestamp":1528109380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Kayo","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsubamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roze","family":"Isono-Nakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nami","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"issue":"6","key":"4520_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/AOG.0b013e3181fb8045","volume":"116","author":"M Frumovitz","year":"2010","unstructured":"Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, et al. Primary malignant melanoma of the vagina. Obstet Gynecol. 2010;116(6):1358\u201365.","journal-title":"Obstet Gynecol"},{"key":"4520_CR2","doi-asserted-by":"publisher","unstructured":"Udager AM, Frisch NK, Hong LJ, Stasenko M, Johnston CM, Liu JR, et al. Gynecologic melanomas: a clinicopathologic and molecular analysis. Gynecol Oncol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.023\n                    \n                  .","DOI":"10.1016\/j.ygyno.2017.08.023"},{"issue":"2","key":"4520_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"SP D'Angelo","year":"2017","unstructured":"D'Angelo SP, Larkin J, Sosman JA, Lebb\u00e9 C, Brady B, Neyns B, et al. Efficacy and safety of Nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226\u201335.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4520_CR4","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3892\/ol.2017.6325","volume":"14","author":"H Tsubamoto","year":"2017","unstructured":"Tsubamoto H, Ueda T, Inoue K, Sakata K, Shibahara H, Sonoda T. Repurposing itraconazole as an anticancer agent. Oncol Lett. 2017;14(2):1240\u20136.","journal-title":"Oncol Lett"},{"issue":"5","key":"4520_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JTO.0b013e31828c3950","volume":"8","author":"CM Rudin","year":"2013","unstructured":"Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, et al. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2013;8(5):619\u201323.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4520_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","volume":"18","author":"ES Antonarakis","year":"2013","unstructured":"Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist. 2013;18(2):163\u201373.","journal-title":"Oncologist"},{"issue":"8","key":"4520_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","volume":"32","author":"DJ Kim","year":"2014","unstructured":"Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745\u201351.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4520_CR8","first-page":"2481","volume":"34","author":"H Tsubamoto","year":"2014","unstructured":"Tsubamoto H, Sonoda T, Yamasaki M, Inoue K. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer. Anticancer Res. 2014;34(5):2481\u20137.","journal-title":"Anticancer Res"},{"issue":"7","key":"4520_CR9","first-page":"3839","volume":"34","author":"H Tsubamoto","year":"2014","unstructured":"Tsubamoto H, Sonoda T, Inoue K. Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer. Anticancer Res. 2014;34(7):3839\u201344.","journal-title":"Anticancer Res"},{"issue":"7","key":"4520_CR10","first-page":"4191","volume":"35","author":"H Tsubamoto","year":"2015","unstructured":"Tsubamoto H, Sonoda T, Ikuta S, Tani S, Inoue K, Yamanaka N. Combination chemotherapy with itraconazole for treating metastatic pancreatic cancer in the second-line or additional setting. Anticancer Res. 2015;35(7):4191\u20136.","journal-title":"Anticancer Res"},{"issue":"9","key":"4520_CR11","first-page":"4923","volume":"35","author":"H Tsubamoto","year":"2015","unstructured":"Tsubamoto H, Sonoda T, Ikuta S, Tani S, Inoue K, Yamanaka N. Impact of itraconazole after first-line chemotherapy on survival of patients with metastatic biliary tract cancer. Anticancer Res. 2015;35(9):4923\u20137.","journal-title":"Anticancer Res"},{"issue":"17","key":"4520_CR12","doi-asserted-by":"publisher","first-page":"28510","DOI":"10.18632\/oncotarget.15324","volume":"8","author":"G Liang","year":"2017","unstructured":"Liang G, Liu M, Wang Q, Shen Y, Mei H, Li D, et al. Itraconazole exerts its anti-melanoma effect by suppressing hedgehog, Wnt, and PI3K\/mTOR signaling pathways. Oncotarget. 2017;8(17):28510\u201325.","journal-title":"Oncotarget"},{"issue":"8","key":"4520_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/cncr.30473","volume":"123","author":"JY Hou","year":"2017","unstructured":"Hou JY, Baptiste C, Hombalegowda RB, Tergas AI, Feldman R, Jones NL, et al. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Cancer. 2017;123(8):1333\u201344.","journal-title":"Cancer"},{"issue":"2","key":"4520_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"6","key":"4520_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/02841860902974167","volume":"48","author":"IM Desar","year":"2009","unstructured":"Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol. 2009;48(6):927\u201331.","journal-title":"Acta Oncol"},{"issue":"1","key":"4520_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.eururo.2014.10.034","volume":"68","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Massari F, Albiges L, Loriot Y, Massard C, Fizazi K, et al. Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol. 2015;68(1):154\u201360.","journal-title":"Eur Urol"},{"issue":"2","key":"4520_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","volume":"19","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19(2):577\u201383.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4520_CR18","first-page":"473","volume":"7","author":"MA Warso","year":"2001","unstructured":"Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, et al. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res. 2001;7(3):473\u20137.","journal-title":"Clin Cancer Res"},{"key":"4520_CR19","doi-asserted-by":"publisher","unstructured":"De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol. 2017. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2017.2908.","DOI":"10.1001\/jamaoncol.2017.2908."},{"issue":"12","key":"4520_CR20","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/jps.20963","volume":"96","author":"A Gupta","year":"2007","unstructured":"Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007;96(12):3226\u201335.","journal-title":"J Pharm Sci"},{"issue":"8","key":"4520_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.7150\/jca.10865","volume":"6","author":"L Zhou","year":"2015","unstructured":"Zhou L, Yang K, Andl T, Wickett RR, Zhang Y. Perspective of targeting Cancer-associated fibroblasts in melanoma. J Cancer. 2015;6(8):717\u201326.","journal-title":"J Cancer"},{"issue":"12","key":"4520_CR22","doi-asserted-by":"publisher","first-page":"19780","DOI":"10.18632\/oncotarget.15540","volume":"8","author":"L Ziani","year":"2017","unstructured":"Ziani L, Safta-Saadoun TB, Gourbeix J, Cavalcanti A, Robert C, Favre G, et al. Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget. 2017;8(12):19780\u201394.","journal-title":"Oncotarget"},{"issue":"7","key":"4520_CR23","first-page":"3521","volume":"37","author":"T Ueda","year":"2017","unstructured":"Ueda T, Tsubamoto H, Inoue K, Sakata K, Shibahara H, Sonoda T. Itraconazole modulates hedgehog, WNT\/\u03b2-catenin, as well as Akt Signalling, and inhibits proliferation of cervical Cancer cells. Anticancer Res. 2017;37(7):3521\u20136.","journal-title":"Anticancer Res"},{"key":"4520_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1021\/acschembio.6b00849","volume":"12","author":"SA Head","year":"2017","unstructured":"Head SA, Shi WQ, Yang EJ, Nacev BA, Hong SY, Pasunooti KK, et al. Simultaneous targeting of NPC1 and VDAC1 by Itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis. ACS Chem Biol. 2017;12:174\u201382.","journal-title":"ACS Chem Biol"},{"issue":"2","key":"4520_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1601-0825.2004.01057.x","volume":"11","author":"AM Contucci","year":"2005","unstructured":"Contucci AM, Inzitari R, Agostino S, Vitali A, Fiorita A, Cabras T, et al. Statherin levels in saliva of patients with precancerous and cancerous lesions of the oral cavity: a preliminary report. Oral Dis. 2005;11(2):95\u20139.","journal-title":"Oral Dis"},{"key":"4520_CR26","unstructured":"The Human Protein Atlas. \n                    https:\/\/www.proteinatlas.org\/ENSG00000126549-STATH\/tissue\n                    \n                  . Accessed 6 May 2018."},{"issue":"3","key":"4520_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CMR.0b013e32832bbde6","volume":"19","author":"T Eisen","year":"2009","unstructured":"Eisen T, Thomas J, Miller WH Jr, Gore M, Wolter P, Kavan P, et al. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res. 2009;19(3):185\u201392.","journal-title":"Melanoma Res"},{"issue":"6","key":"4520_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/bjc.2013.477","volume":"109","author":"R Plummer","year":"2013","unstructured":"Plummer R, Lorigan P, Brown E, Zaucha R, Moiseyenko V, Demidov L, et al. Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. Br J Cancer. 2013;109(6):1451\u20139.","journal-title":"Br J Cancer"},{"issue":"124","key":"4520_CR29","first-page":"870","volume":"60","author":"H Duanmin","year":"2013","unstructured":"Duanmin H, Chao X, Qi Z. eEF1A2 protein expression correlates with lymph node metastasis and decreased survival in pancreatic ductal adenocarcinoma. Hepato-Gastroenterology. 2013;60(124):870\u20135.","journal-title":"Hepato-Gastroenterology"},{"issue":"2","key":"4520_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.canlet.2009.04.001","volume":"283","author":"M Greco","year":"2009","unstructured":"Greco M, Mitri MD, Chiriac\u00f2 F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett. 2009;283(2):222\u20139.","journal-title":"Cancer Lett"},{"issue":"17","key":"4520_CR31","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1002\/pmic.200500093","volume":"5","author":"KR Kozak","year":"2005","unstructured":"Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5(17):4589\u201396.","journal-title":"Proteomics"},{"issue":"1","key":"4520_CR32","doi-asserted-by":"publisher","first-page":"73.e1","DOI":"10.1016\/j.ajog.2009.07.049","volume":"202","author":"G Farias-Eisner","year":"2010","unstructured":"Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol. 2010;202(1):73.e1\u20135.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"4520_CR33","first-page":"31","volume":"5","author":"CM Maciel","year":"2005","unstructured":"Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G, et al. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 2005;5(1):31\u20138.","journal-title":"J Exp Ther Oncol"},{"issue":"3","key":"4520_CR34","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/bjd.12426","volume":"169","author":"J Lade-Keller","year":"2013","unstructured":"Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Br J Dermatol. 2013;169(3):618\u201328.","journal-title":"Br J Dermatol"},{"issue":"4","key":"4520_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12032-018-1104-9","volume":"35","author":"D Cio\u0142czyk-Wierzbicka","year":"2018","unstructured":"Cio\u0142czyk-Wierzbicka D, Laidler P. The inhibition of invasion of human melanoma cells through N-cadherin knock-down. Med Oncol. 2018;35(4):42.","journal-title":"Med Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4520-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T19:06:52Z","timestamp":1559588812000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4520"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4520-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"26 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was a part of a clinical trial titled \u2018Prospective evaluation of the molecular effects of itraconazole as an anti-cancer agent: a window of opportunity study\u2019, which was approved by the institutional review board of Hyogo College of Medicine (No. 282). Authors obtained written informed consent and publication consent from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"630"}}